A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma

Cancer type: Melanoma

Phase: II

Principal Investigator: Nyakas Martha

Country: NO

Keywords: Norway, Oslo, UV1-202

Status: Open for inclusion

Link to